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Abstract
Background: HIV remains a major public health issue, especially in Eastern and Southern Africa. Pre-exposure
prophylaxis is highly effective when adhered to, but its effectiveness is limited by cost, user acceptability and
uptake. The cost of a non-inferiority phase III trial is likely to be prohibitive, and thus, it is essential to select the best
possible drug, dose and schedule in advance. The aim of this study, the Combined HIV Adolescent PrEP and
Prevention Study (CHAPS), is to investigate the drug, dose and schedule of pre-exposure prophylaxis (PrEP) required
for the protection against HIV and the acceptability of PrEP amongst young people in sub-Saharan Africa, and
hence to inform the choice of intervention for future phase III PrEP studies and to improve strategies for PrEP
implementation.
Methods: We propose a mixed-methods study amongst young people aged 13–24 years. The first component
consists of qualitative research to identify the barriers and motivators towards the uptake of PrEP amongst young
people in South Africa, Uganda and Zimbabwe. The second component is a randomised clinical trial
(ClinicalTrials.gov NCT03986970, June 2019) using a novel ex vivo HIV challenge method to investigate the optimal
PrEP treatment (FTC-TDF vs FTC-TAF), dose and schedule. We will recruit 144 amongst HIV-negative uncircumcised
men aged 13–24 years from voluntary male medical circumcision clinics in two sites (South Africa and Uganda) and
randomise them into one of nine arms. One group will receive no PrEP prior to surgery; the other arms will receive
either FTC-TDF or FTC-TAF, over 1 or 2 days, and with the final dose given either 6 or 20 h prior to surgery. We will
conduct an ex vivo HIV challenge on their resected foreskin tissue.
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Discussion: This study will provide both qualitative and quantitative results to help decide the optimum drug, dose
and schedule for a future phase III trial of PrEP. The study will also provide crucial information on successful
strategies for providing PrEP to young people in sub-Saharan Africa.
Trial registration: ClinicalTrials.gov NCT03986970. Registered on 14 June 2019
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Background
HIV remains a major public health issue, especially in
sub-Saharan Africa (SSA). Globally, there were an esti-
mated 4700 new infections every day in 2018, with
around 2000 of these in Eastern and Southern Africa [1].
A key goal towards ending the epidemic is the UNAIDS
90-90-90targets, set in 2014, that at least 73% of people
living with HIV should achieve viral suppression by 2020
and 86% by 2030. Despite progress towards these goals,
new strategies to protect against HIV infection are
urgently needed.
Daily pre-exposure prophylaxis (PrEP) is highly effect-
ive when adhered to, but its effectiveness is limited by
cost, user acceptability and uptake [2]. Event-based
PrEP, defined as taking tablets before and after insertive
sex, has been shown to be highly effective in men who
have sex with men (MSM), but roll-out has been limited
by lack of data in other populations and concerns about
regime complexity and burden. The IPERGAY rando-
mised controlled trial (RCT) demonstrated that PrEP, in
the form of FTC-TDF (Truvada), reduced the rate of in-
fection by 86% (95% CI 40–98%) amongst men who have
unprotected receptive and insertive anal sex with men
[3]. This trial used a schedule of two pills 2–24 h before
sex, a third pill 24 h after the previous dose and a final
pill 24 h later.
Tenofovir alafenamide (TAF) is a newer version of
TDF with fewer renal and bone side effects than TDF
and, in combination with FTC, has a smaller pill size
than FTC-TDF. In vitro data show concentrations of
TFV-diphosphate in PBMCs are 8- to 10-fold higher
following oral FTC-TAF compared to oral FTC-TDF.
However, the optimum regime for insertive sex is not
known and could be at a lower dose than for recep-
tive sex given the lower transmission risk. This pro-
vides a rationale for exploring whether lower doses of
FTC-TAF are required for on-demand PrEP compared
with daily PrEP [4]. Evidence for the efficacy of novel
PrEP regimes would require a non-inferiority rando-
mised controlled trial (RCT) with the standard FTC-
TDF regimen as the comparison arm. However, due
to the high efficacy of FTC-TDF, a very low incidence
of HIV infection would be expected in the FTC-TDF
arm, with consequent large sample sizes. The cost of
such a phase III trial is prohibitive [5], and hence, it
is unlikely that more than one candidate drug, dose
and schedule will be tested in one trial. Therefore, it
is essential to select the best possible candidate in ad-
vance of a phase III RCT.
An innovative solution is the use of ex vivo challenge,
which in this context uses tissue biopsies taken from an
individual who has received HIV prevention medication
in vivo. The freshly resected tissue is then exposed to
HIV in a laboratory setting. After a washout, the tissue
supernatant is cultured for 3 weeks, with culture super-
natants harvested to establish the level of HIV infection.
The most commonly used endpoint for cervical, rectal
and vaginal tissue has been levels of p24 antigen in cul-
ture supernatant [6].
Our proposed study, the Combined HIV Adolescent
PrEP and Prevention Study (CHAPS), is a mixed-
methods research programme which aims to inform the
choice of intervention for future phase III PrEP studies
in young people in sub-Saharan Africa and to improve
strategies for PrEP implementation.
Methods
The CHAPS study will consist of a social science
study and an RCT. The social science components
will use individual interviews, group discussions and
quantitative surveys to explore the preferences of
PrEP dosing, schedule, cost and access. The RCT will
investigate the optimum on-demand PrEP dose and
schedule for insertive sex of FTC-TDF and FTC-TAF
using an ex vivo model of HIV infection in resected
foreskins from men recruited for voluntary medical
male circumcision (VMMC). This strategy ensures
that the study will be relatively quick and cheap and
will not expose men to any additional HIV risk. The
study will start with the social science qualitative
component, followed by the quantitative survey and
RCT.
Settings
The study will take place in four sites: Soweto and Cape
Town in South Africa, Entebbe in Uganda and Chitun-
gwiza in Zimbabwe. The RCT will take place only in So-
weto and Entebbe.
In South Africa, the study will be conducted by the
Perinatal HIV Research Unit at Wits University and the
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Desmond Tutu HIV Centre in Soweto and Cape Town.
Soweto is located in the south-west of Johannesburg city,
in Gauteng province, where the estimated HIV preva-
lence is 15% amongst 15–49-year-olds. In Cape Town,
the study will take place in the Klipfontein/Mitchells
plain district, located in the southern part of the Cape
Town Metro, where HIV prevalence is 24%, the highest
in the Western Cape.
In Uganda, the study will be conducted around En-
tebbe town, in Wakiso district, 40 km south of the cap-
ital, Kampala. Participants will be recruited from
amongst people living in fishing communities, where
HIV prevalence is estimated at 27% amongst 15–49-
year-olds [7] and 20% in 15–24-year-olds [8]. Research
in Uganda will be conducted by the Medical Research
Council/Uganda Virus Research Institute and London
School of Hygiene & Tropical Medicine Uganda Re-
search Unit.
In Zimbabwe, the study will be conducted by the Uni-
versity of Zimbabwe College of Health Sciences Clinical
Trials Unit in Chitungwiza, a city in Harare Province
about 25 km south of Harare. HIV prevalence is esti-
mated to be 7.3% amongst 20–24-year-olds in this prov-
ince [9].
Social science methodology
There are three sections to the social science re-
search: group discussions (GDs), in-depth interviews
(IDIs) and quantitative surveys (QS). The GDs and
IDIs will be used to collect exploratory qualitative
data to assess the perceptions (barriers and motiva-
tors) towards daily and on-demand PrEP amongst
HIV-negative young people aged 13–24 years. The
quantitative survey data will be collected from the
same population and will be used to investigate
demographics and socio-behavioural risk factors re-
lated to PrEP preferences amongst young people.
Sample size and recruitment
We will recruit equal numbers of male and female
volunteers aged 13–24 years and willing to take a HIV
test. All participants will be recruited through purpos-
ive community sampling. Exclusion criteria will be
positive HIV status (except for the survey in Uganda)
and evidence of a psychological/psychiatric disorder
that would invalidate informed consent. Parental wai-
ver of consent was approved by ethical boards for use
in Cape Town, Entebbe and Chitungwiza. Once
recruited for one component of the research (GD,
IDI, QS), an individual will not be eligible for any
other component. For South Africa and Zimbabwe,
participants will be recruited from community groups,
schools, churches, bars, taxi ranks and other public
meeting places. In Uganda, participants will be
recruited at fish landing sites with information on the
study being provided through local leaders, Village
Health Teams and project mobilisers.
We will enrol up to 192 people for GDs (8 groups per
country, with 6–8 participants per group) and 60 for
IDIs (20 per country). In addition, we will conduct 20
IDIs amongst RCT participants (10 per country) and re-
searchers. For the QS, we will enrol 1300 participants
with an equal gender ratio and stratification for specific
age groups, with more participants in Uganda (n = 500)
than in the other countries (n = 400) due to the inclusion
of people living with HIV. As the study is descriptive, no
formal sample size calculation has been performed.
Recruitment in SA will be split equally between the two
sites.
Acceptability of PrEP data collection methods
Group discussions will be used to identify attributes re-
lating to PrEP which will include frequency of adminis-
tration (i.e. daily vs on-demand PrEP), dispensing site
(i.e. ARV clinic, pharmacy), time to be spent obtaining
PrEP, frequency of collecting PrEP and frequency of
HIV testing associated with PrEP. Interview guides for
GDs and IDIs will be used to investigate topics including
attitudes towards daily and on-demand PrEP and any
relation with HIV risk. Barriers (e.g. stigma related to
taking ARV medication) and motivators (e.g. using PrEP
for HIV prevention) to PrEP will be explored, and ap-
proaches will be developed to maximise adherence to
avoid PrEP failure (and consequent drug-resistant HIV)
and to retain people in PrEP programmes. The guides
will address multiple delivery options for PrEP uptake
(Table 1). The interview guide will be pilot-tested
amongst adolescent Community Advisory Boards
(CABs) in each country.
The survey will consist of closed questions, and in So-
weto and Cape Town, a discrete choice experiment
(DCE) will also be included. These will be administered
to participants using electronic tablets with the Open
Data Kit (ODK) application. The survey will cover PrEP
preferences, sexual behaviour, views on HIV, mental
health and alcohol and drug use. The DCE will investi-
gate participants’ preferences on daily or on-demand
PrEP, cost and access to PrEP.
Analysis of social science data
GDs and IDIs will be transcribed and analysed using a
framework analysis approach. This provides a highly
systematic method of categorising and organising data
according to key themes, concepts and emergent
categories in grids or matrices. The aim is to link quali-
tative findings with quantitative research [10] to contrast
and enhance findings collected quantitatively and to in-
crease the validity of findings through triangulation [11].
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Data analysis will be undertaken by experienced
qualitative researchers who have been provided with
specific training in framework analysis, to ensure a
consistent approach to analysis. The first five tran-
scripts from each site will be coded by at two
researchers at each research site and assessed for
consistency. Differences will be resolved and a list of
final codes shared with all sites. The remaining tran-
scripts will be coded by at least one research analyst
at each study site.
To gain qualitative feedback on the clinical trial imple-
mentation and use/perceptions of PrEP, in-depth inter-
views conducted with participants and health workers
during trial exit visits will be analysed using the same
data analysis methods discussed above.
Survey responses will be tabulated by age group,
sex and site. The initial results will show the propor-
tions of responses in each category for the survey
questions. The main contrasts we will investigate are
between people who prefer on-demand PrEP with
those who prefer daily PrEP, and the acceptability of
oral PrEP. For these analyses, respondents who an-
swer “not sure” or “no preference” will be excluded.
We will conduct multivariable logistic regression to
investigate which factors influence PrEP preference.
All regression models will be adjusted for sex, age
group and site.
Methodology for the randomised controlled trial
The intervention, conducted in Soweto and Entebbe,
consists of either FTC-TDF or FTC-TAF, in various
doses and schedules. The outcome will be HIV infec-
tion of the resected foreskin in an ex vivo challenge.
The trial was registered with ClinicalTrials.gov on 14
June 2019, with identifier NCT03986970. Recruitment
rates and safety will be overseen by an independent
data safety monitoring committee (DSMC) who re-
ports to the Trial Steering Committee (TSC) and
comprises a statistician and two leading HIV preven-
tion research clinicians. The DSMC will review the
trial’s progress including recruitment, data quality,
adherence to protocol treatment and follow-up, and
safety outcomes. Members are independent from the
sponsor and have no competing interests. They will
meet once at the beginning of the trial, once after ten
participants have completed the study and once ap-
proximately halfway through recruitment or after
6 months (whichever is the earliest). The committee
may meet more frequently if it becomes necessary to
do so. The TSC is the oversight body and meets at
least annually. There are 5 voting independent
members (including the Chair) and 4 voting non-
independent members including the trial PIs. Based
on the recommendations from the DSMC, possible
decisions by the TSC include early stopping due, for
example, to clear benefit or harm of a treatment, fu-
tility, insufficient recruitment or external evidence;
stopping recruitment within a site; modifying target
recruitment or pre-analysis follow-up, based on any
developments; and sanctioning and/or proposing
protocol changes.
The trial has independent audit monitoring which is
independent from investigators and the sponsor. The
trial is monitored externally throughout the study and
occurs independently from investigators and the
sponsor.
Recruitment
The target sample size is 144 men, with equal num-
bers in South Africa and Uganda. As the trial is de-
scriptive, no formal sample size calculation has been
performed. The sample size of 8 participants per
country was based on previous ex vivo challenge
models using rectal and vaginal tissue. As there was
considerable tech transfer, we chose to carry out 8
per country instead of 8 total per group. Participants
will be drawn from men attending one of two VMMC
clinics (Chris Hani Baragwanath Academic Hospital,
Soweto, South Africa, and Entebbe General Hospital,
Entebbe) or volunteers from the surrounding commu-
nities. The eligibility criteria are age 13–24 years,
HIV-negative, clinically eligible for circumcision,
weigh more than 35 kg, have a haemoglobin more
than 9 g/L and be able to understand and sign a
Table 1 Topics of inquiry for group discussions and in-depth interviews
Topic Prompts
PrEP characteristics PrEP attributes including side effects, effectiveness, dosage, cost, dispensing (where and who)
Behavioural change after
PrEP
Own risk perceptions on HIV, peer sexual norms, knowledge about HIV and HIV risk, multiple partners and transitional
sex, condom use, sexual disinhibition on PrEP use
PrEP in general Knowledge, perceptions and preferences about PrEP
Acceptability of PrEP Willingness to use and receptiveness towards PrEP, reasons to use or not use PrEP
Facilitators and barriers Social and community concerns regarding PrEP
Gender dynamics Disclosure to partners, perceptions of partners taking PrEP
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written informed consent form (for participants under
18, the legal guardian must also sign). Participants
must satisfy all eligibility criteria within 21 days prior
to their circumcision visit. No personal identifiable in-
formation will be shared or used in the analysis.
Design and intervention
Enrolled participants will be randomised prospectively
into one of nine groups in equal ratios, stratified by
country (n = 144; 8 participants per group per country).
Randomisation envelopes will be prepared by staff who
were otherwise not involved in the CHAPS study. The
randomisation will ensure there will be exactly eight par-
ticipants per group in each country using block alloca-
tion, with blocks of size 9 and 18, prepared using the
Stata command ralloc. During data analysis, the trial
statistician will only be given dummy identifiers for each
trial arm, so that summary statistics can be produced.
The true group identifiers will only be revealed when the
analysis is complete. Of the nine groups, eight will re-
ceive active treatment and one will be a control group
where the men do not receive any PrEP (Fig. 1, Table 1).
The eight treatment arms form a 2 × 2 × 2 factorial de-
sign, on three factors:
i. Drug: FTC-TDF or FTC-TAF
ii. Dose: either three tablets over 2 days or two tablets
on 1 day
iii. Timing of VMMC: 5 or 21 h following the final
dose of PrEP
The two drugs to be compared are FTC-TDF (also
known as Truvada), which is a combination of emtricita-
bine (200 mg) and tenofovir disoproxil fumarate (300
mg, which is equivalent to 245 mg of tenofovir diso-
proxil) and FTC-TAF (known as Descovy), which is
emtricitabine (200 mg) and tenofovir alafenamide (25
mg). All regimes will be taken as directly observed ther-
apy doses administered by research staff. The timing of
the VMMC will be either 5 or 21 h after the final dose of
PrEP. There will be a 1-h permissible allowance either
side of this time, so that the two windows will be 4–6 h
or 20–22 h following the final PrEP tablet. Participants
will also provide blood and urine samples, will be
screened for STIs and will be invited to provide optional
rectal, urethral and coronal sulcus swabs. If a participant
is diagnosed as HIV-positive at screening, then they are
referred immediately to services for follow-up and care.
Any sexually transmitted infections diagnosed will be
treated by the trial team.
Fig. 1 Flow diagram of participant and foreskin journey for primary analysis (oral PrEP only). The numbers in the black boxes indicate the
randomisation groups—there are nine, with each man allocated to exactly one group, with each group equally likely. This figure shows
recruitment from both sites; recruitment will be split equally between SA (n = 72) and Uganda (n = 72). The numbers in the green boxes refer to
the analysis groups. The main comparison will be between groups A–D. Group X, men who do not receive PrEP, will be used as a comparison
and to ensure that the ex vivo challenge model is successful
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At the VMMC visit or the final study visit (post-
VMMC), all participants will complete a self- or
interviewer-administered short exit survey using the
electronic database, ODK and/or iDatafax. Questions
will focus on motivation and concerns for trial participa-
tion, sexual behaviour, PrEP acceptability (for partici-
pants who took PrEP) and clinical trial experience. The
survey will take approximately 5 min to complete. The
exit survey will be translated into the main local lan-
guages of each country (South Africa: Zulu, Sesotho;
Uganda: Luganda). Retention is promoted by the short
duration of the trial. The intervention is the PrEP dose
which is administered at most twice with the final dose
either 5 h or 21 h before circumcision.
Ex vivo challenge
Foreskin tissue will be challenged ex vivo with HIV-
1BaL within 1 h of resection. Further post-exposure
dosing (using the same drug taken by the participant)
will be given to the resected foreskin following HIV
exposure to simulate the effect offered by PrEP drugs
taken after sex. The presence and level of HIV infec-
tion will be assessed by p24 antigen ELISA on fore-
skin culture supernatants from days 3, 7, 11 and 15
days. All cultures will be initiated immediately after
circumcision in local laboratories within 30 min travel
time from the VMMC clinic.
Each foreskin will be cut into segments (explants) to
allow evaluation of each dose in three biological repli-
cates. Results from explant challenge with the same viral
titre will be combined by taking the mean, giving a sin-
gle measurement for each participant. The outcome
measures will be as follows:
1. p24 at day 15
2. Slope of p24 curve, days 3–15
3. p24 area under the curve, days 3–15
We will test two HIV challenge titres; a high titre (104
TCID50/ml) normally used in pre-clinical assays in the
laboratory and a low titre (102 TCID50/ml) trying to
mimic in vivo levels. Results from these two challenge
titres will be considered separately and will not be com-
bined. Data from the two countries will be combined for
analysis. There will be four active treatment analysis
groups (A–D, Table 2) and one control group (no PrEP;
X in Table 2). We will combine the randomisation arms
where men take the same drug, at the same dose, differ-
ing only in the time between the final dose and circum-
cision, unless the result of any particular outcome is
markedly different (Table 3). Hence, there will be 32
men in each analysis group, except for the control group
(N = 16).
Qualitative interviews
We will conduct in-depth entry and exit interviews
amongst a subset of RCT participants, to gain qualita-
tive feedback on the clinical trial implementation and
use of PrEP. Ten participants per site will be
randomly selected. All research will be conducted in
a local language of each country (South Africa: Zulu,
Sesotho; Uganda: Luganda; Zimbabwe: English,
Shona). Parental/guardian consent will be obtained
for adolescents younger than 18 years. We will also
conduct interviews with the trial health care providers
to seek their perspective on the nature of PrEP
experiences.
Data management for the RCT
Protocol and data management training will be con-
ducted prior to study initiation by the protocol team.
Data will be collected at the site and recorded in partici-
pant chart binders, which will be reviewed for accuracy
and completeness prior to participants leaving the clinic.
Source data transcribed onto case report forms (CRFs)
will be reviewed for completeness and transcription
errors prior to data being entered into the REDCAP
database. The REDCap database and programmed data
cleaning queries and activities will be mapped in collab-
oration with the study team and outlined in the study
data quality management plan. The REDCap database
will have inbuilt edit checks and skip logic that is inter-
actively activated on data entry prompting query reso-
lution. Additionally, data will be extracted and reviewed
bi-monthly using additional queries programmatically
generated using the SAS software. These data queries
will be sent to the sites by means of a quality control
(QC) report every 2 weeks. Study management reports
will also be circulated to the sites and the protocol team
every week.
To ensure data confidentiality, participant identifiers
will not be recorded on study CRFs and consequently
not in the study database. REDCap is housed on se-
cured servers and administratively managed by the
University of the Witwatersrand in Johannesburg
South Africa. User access and database permissions
are controlled through unique individual login cre-
dentials that required to be updated every 90 days.
The database will have an inbuilt audit trail as well,
and study data will be shared only with the trial stat-
istician. Study data will be password protected and
encrypted before transfer.
Adverse events will be collected systematically (i.e.
asked specifically of participants at follow-up visits). Un-
expected adverse events will be collected on AE and
SAE forms. SAEs will be reported in trial publications,
by trial arm.
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Primary endpoint
HIV infection will be assessed via measurement of
p24 antigen. There will be three main HIV infection
outcomes, as above, which will each be considered of
equal weight when determining the efficacy of each
treatment regimen. The primary comparison will be
between groups A–D, as described in Figs. 1 and 2.
These will be no formal statistical comparison be-
tween the groups as we are not powered to detect
any particular difference, as the variability of the p24
responses is not known in this context. Instead, the
means and standard deviations for each outcome in
each group will be presented to allow comparison be-
tween the groups. We will present 95% confidence in-
tervals to report the uncertainty of each estimate;
however, we expect these intervals to overlap for all
groups due to the small group sizes. The control
group will be used to assess the effectiveness of the
ex vivo challenge process.
Participants and care providers will not be blinded, but
outcome assessors and data analysts will be. If the data
safety monitoring board wish to see unblinded data, this
will be provided by the independent statistician. The
trial statistician will be given dummy group identifiers
for each participant, so that means can be calculated for
each group, but will not know which treatment each
group received until group differences have been
computed.
Secondary endpoints
Additional analyses will be performed to assess the phar-
macokinetic characteristics and investigate the added ef-
fect of post-exposure dosing of PrEP drugs. We will
compare drug levels (TFV, FTC, TAF) in the plasma,
peripheral blood mononuclear cells CD4 T cells (TFV-
DP and FTC-TP) and rectal fluid. In addition, foreskin
inflammation, microbiome phenotype and cellular acti-
vation of foreskin tissue following PrEP initiation will be
investigated.
Sample storage
Biological samples will be stored in a repository ap-
proved by the University of the Witwatersrand Bioethics
Research Committee (Table 4). Any future use will be
according to the requirements of the University of the
Witwatersrand’s Human Research Ethics Committee
Table 2 Table of participant randomisation groups and laboratory analysis of foreskins
Stage 1: Oral PrEP taken by men Foreskin tissue
divided in the lab
Stage 2: In vitro dosing of tissue in the laboratory
Randomised
arm
N Oral PrEP
analysis
group
Oral
drug
Number of
PrEP doses
Interval between
last oral PrEP and
VMMC (h)
In vitro
analysis
group
In vitro
drug
Interval between ex vivo
HIV exposure and in vitro
dose (h)
1 16 X No PrEP – – X-0 No PrEP –
X-TDF FTC-TDF 18
X-TAF FTC-TAF 18
2 16 A FTC-TDF 1 5 A-5-0 No PrEP –
A-5-TDF FTC-TDF 18
3 16 FTC-TDF 1 21 A-21-0 No PrEP –
A-21-TDF FTC-TDF 18
4 16 B FTC-TDF 2 5 B-5-0 No PrEP –
B-5-TDF FTC-TDF 18
5 16 FTC-TDF 2 21 B-21-0 No PrEP –
B-21-TDF FTC-TDF 18
6 16 C FTC-TAF 1 5 C-5-0 No PrEP –
C-5-TAF FTC-TAF 18
7 16 FTC-TAF 1 21 C-21-0 No PrEP –
C-21-TAF FTC-TAF 18
8 16 D FTC-TAF 2 5 D-5-0 No PrEP –
D-5-TAF FTC-TAF 18
9 16 FTC-TAF 2 21 D-21-0 No PrEP –
D-21-TAF FTC-TAF 18
The in vitro analysis groups comprise three components: a letter indicating the stage 1 group, a number (5 or 21) indicating the interval between the last oral
PrEP dose and circumcision and an item indicating in vitro dosing (where 0 = no dose). The exceptions are the group of men who did not receive oral PrEP (group
X): these groups do not include the middle component
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(medical). In brief, the requirements are (1) all partici-
pants whose specimens are collected for repository stor-
age must have provided consent for this, (2) repository
samples may not only be used for a purpose that in-
cluded in the original repository or trial/study informed
consent, and (3) the University of the Witwatersrand
HREC must be notified of the future use. There is no
time-bound requirement placed on the investigators for
repository storage.
Trial status
Recruitment commenced in South Africa on 11 Novem-
ber 2019. Recruitment was hoped to start in Uganda in
January 2020. We expect to complete the recruitment in
both sites in August 2020. South Africa is operating
under version 1.0 of the protocol, dated 8 August 2018.
Uganda is using a slightly amended version, 1.2 (12 No-
vember 2018) which includes changes requested by the
local ethics committee to account for site-specific
Table 3 Summary of randomisation arms
Randomised arm Drug Number Dose 1 Dose 2 (24 h later)
(± 1 h)
Interval between the last PrEP
dose and surgery (h) (± 1 h)
Analysis group (Fig. 1)
1 Control 16 – – – X
2 FTC-TDF 16 2 tablets – 5 A
3 FTC-TDF 16 2 tablets – 21 A
4 FTC-TDF 16 2 tablets 1 tablet 5 B
5 FTC-TDF 16 2 tablets 1 tablet 21 B
6 FTC-TAF 16 2 tablets – 5 C
7 FTC-TAF 16 2 tablets – 21 C
8 FTC-TAF 16 2 tablets 1 tablet 5 D
9 FTC-TAF 16 2 tablets 1 tablet 21 D
Fig. 2 Flow diagram of participant and foreskin journey for oral PrEP, in vitro drug exposure and ex vivo HIV challenge. The analysis group
identifiers in stage 2 comprise three components: a letter indicating the stage 1 group, a number (5 or 21) indicating the interval between the
last oral PrEP dose and circumcision and an item indicating in vitro dosing (where 0 = no dose). The exceptions are the group of men who did
not receive oral PrEP (Group X): these groups do not include the middle component
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procedures around hospitalisation and partner notifica-
tion. A SPIRIT figure is included as Fig. 3, with a check-
list included as a supplementary file.
Dissemination plans
A whole or part of this trial results will be communi-
cated, orally presented and/or published in appropri-
ate scientific journals. Full anonymity of participant’s
details will be maintained throughout. Participants
wanting to see the results of the trial can request a
copy of the article from the investigators once it has
been published. We will follow standard authorship
eligibility guidelines and will not use professional
writers. The full protocol, participant-level dataset
and statistical code will be publicly available on de-
mand through the LSHTM Data Compass platform.
Discussion
This innovative mixed-methods, multi-country study will
assess the effectiveness and acceptability of PrEP medi-
cation amongst young people in sub-Saharan Africa.
The use of ex vivo challenge will enable us to quickly
and affordably provide a first assessment of the efficacy
of a range of PrEP drugs, doses and schedules for inser-
tive sex. The results from the RCT, combined with the
rich qualitative data from the social science study, will
inform the planning and design of a future phase III trial
of PrEP regimes.
The in-depth interviews, group discussions and
qualitative survey will provide detailed, contextual in-
formation on the ways in which people may take
PrEP. By focusing on sexually active young people, we
plan to design a future trial of PrEP which will be
welcomed by this key population. The inclusion of a
discrete choice experiment will allow us to assess
which factors of the delivery of PrEP are most im-
portant to young people.
A critical feature of this study is the interplay
between the social science and RCT components. In
particular, the experience of recruitment for the sur-
vey will help with recruitment for the RCT, both by
helping our teams on the ground learn by experience,
and by building links with the host communities and
sensitising local residents to the trial. One of the key
strengths of the trial design is the short duration of
participant contact. This reduces the chance of loss
to follow-up and helps to provide a quick answer for
the scientific question. In addition, the skill transfer
of ex vivo challenge to the laboratories in South Af-
rica and Uganda provides significant capacity building.
Unlike studies with HIV incidence as an outcome, no
participants will be exposed to additional risk of HIV
due to group allocation, and we will make it clear to
men that the PrEP doses given will not confer protec-
tion against HIV. The combination of RCT and in-
depth qualitative research will allow for informed
decision-making about the next steps of PrEP dosing
and schedule.
In the survey, we accept that the proportions re-
ported for each group are unlikely to be generalisable
to the wider population because our sampling was
purposeful, rather than random, and it is likely that
we will have recruited young people with different at-
titudes towards PrEP and HIV. The lack of formal
statistical testing is justified by the design and aims of
the RCT. As the aim of the study is to provide guid-
ance for the design of future studies, we will assess
the results of the trial in the light of findings from
the social science element, to assess which combin-
ation of drug, dose and timing will likely be most ef-
fective and acceptable to the target populations. In an
era when efficacy studies for HIV protection are be-
coming prohibitively large and expensive, it is not
feasible to study multiple regimens in a phase III set-
ting. Evidence from phase 2 studies of this nature will
Table 4 Sample collection and sample analysis
Specimen type Volume/amount of sample Analysis
Safety blood 4 ml EDTA Haemoglobin
5 ml SSAT HIV
Research blood 51 ml ACD Ex vivo challenge, drug levels, cytokines
Rectal swab 1 swab Drug levels
Urethral swab 1 swab Inflammation
Coronal sulcus swab 1 swab Microbiome
Foreskin Circumcised foreskin Ex vivo challenge, drug levels, inflammation and microbiome
Urine 5 ml Drug level
5 ml STI screen
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maximise the chance of identifying the most effica-
cious dosing strategy that can progress into efficacy
trials. This factorial design using a surrogate endpoint
can be used to efficiently select drug combinations
and dosing regimens for testing in phase III, while
obviating the unnecessary costs of futile regimens.
We see this study design as vital to providing rapid
stop-go decisions for a range of treatment options in
a cost-effective and timely way. The results from this
study should mean that the risks to participant in a
future trial are minimised by selecting the drug, dose
and schedule which will offer the best protection. The
knowledge we discover should be critical to the de-
sign of future trials.
Fig. 3 SPIRIT figure. *p24 antigen ELISA was carried out until day 15 of culture
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